Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2020 - 2025)

Insight Molecular Diagnostics' Cash from Financing Activities history spans 6 years, with the latest figure at -$120000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 52.94% year-over-year to -$120000.0; the TTM value through Sep 2025 reached $39.2 million, up 309.55%, while the annual FY2024 figure was $20.4 million, 67.64% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$120000.0 at Insight Molecular Diagnostics, down from -$114000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $69.9 million in Q1 2021 and bottomed at -$528000.0 in Q3 2022.
  • The 5-year median for Cash from Financing Activities is -$29000.0 (2023), against an average of $9.7 million.
  • The largest YoY upside for Cash from Financing Activities was 36223.33% in 2024 against a maximum downside of 750.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$269000.0 in 2021, then skyrocketed by 62.83% to -$100000.0 in 2022, then skyrocketed by 70.0% to -$30000.0 in 2023, then surged by 36223.33% to $10.8 million in 2024, then plummeted by 101.11% to -$120000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cash from Financing Activities are -$120000.0 (Q3 2025), -$114000.0 (Q2 2025), and $28.6 million (Q1 2025).